Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Pragmatiston Mar 01, 2021 2:14pm
265 Views
Post# 32686884

RE:RE:Insider Buy

RE:RE:Insider Buy
clubhouse19 wrote: There was a total of about 160 k of shares carried out privately on feb 23 at 6.38 and filed feb 27. 
Looks to me insiderts buying into the bought deal. 

 If so what is the extra  38 cents for if the price was 6.00 per share



Pragmatist wrote:
 
 
I think that new investors will look upon this in a favorable light. 
 
Last summer, when there was a bought deal, insiders sold.  This time they bought. This suggests that in contrast to last summer, there might be some positive follow-on news.
 
I appreciate that life is not  as simple as this, but it is still a positive development.
 
If you believe that insiders such as Legault/Wallace will be rewarded with additional shares for an IP consolidation instead of cash or a combination thereof, then this is doubly good, in that they would purchase  additional shares in advance of such a deal.
 
This buy was a private arrangement for insiders, all on the same date and at the same price. And at a price greater than the offering and without the warrants. So it was a coordinated deal outside the Public Offering (PO). Probably with a single SH(s).  Maybe involving the senior broker warrants?
 
So kudos to management for pursuing this when they might have done better with a private placement (PP), where they could have participated at a lower price and with warrants.
 
This is all pure specualation.  But it gives me a warm and fuzzy feeling that I initially didn't have when the bought deal was initially announced. This is good news. Let's see what evolves.
 




I think that the number of insider shares was closer to 280K, when you factor in Schmed Enterprises and Altapharm Internation, over which Legault/Wallace exercise control or direction..
If you look at the email contact information  for papers by Wallace on the web, it's: altapharm@hotmail, where alta maybe stands for alberta.
 
<< Previous
Bullboard Posts
Next >>